Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AbobotulinumtoxinA for Plantar Fasciitis and Equinus
NCT03978234Phase 2Unknown
- Sponsor
- University Foot and Ankle Foundation
- Start
- Nov 2019
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in plantar fasciitis and equinus deformity, sponsored by University Foot and Ankle Foundation. Primary endpoint: Safety and Effect of Injection at 8 weeks. Status: unknown.
02
Drugs
botulinum toxin type A
03
Conditions
plantar fasciitisequinus deformity
Beyond the preview
Go deeper on NCT03978234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03978234.